Sorrento Therapeutics (SRNE) Upgraded by BidaskClub to Buy
BidaskClub upgraded shares of Sorrento Therapeutics (NASDAQ:SRNE) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.
SRNE has been the subject of several other research reports. Oppenheimer set a $6.00 price objective on shares of Sorrento Therapeutics and gave the stock a buy rating in a research report on Wednesday, November 15th. ValuEngine raised shares of Sorrento Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, January 3rd. Finally, HC Wainwright reaffirmed a buy rating and set a $20.00 price objective on shares of Sorrento Therapeutics in a research report on Monday, September 18th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Sorrento Therapeutics presently has a consensus rating of Buy and an average price target of $11.50.
Shares of Sorrento Therapeutics (NASDAQ:SRNE) opened at $4.90 on Friday. The firm has a market cap of $388.68, a P/E ratio of -11.67 and a beta of 1.04. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.18. Sorrento Therapeutics has a 52-week low of $1.50 and a 52-week high of $6.00.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.